JP2001516717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001516717A5 JP2001516717A5 JP2000511498A JP2000511498A JP2001516717A5 JP 2001516717 A5 JP2001516717 A5 JP 2001516717A5 JP 2000511498 A JP2000511498 A JP 2000511498A JP 2000511498 A JP2000511498 A JP 2000511498A JP 2001516717 A5 JP2001516717 A5 JP 2001516717A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- methylpiperazin
- tetrahydro
- naphthyl
- benzopyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000003727 serotonin 1A antagonist Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000004000 serotonin 1B antagonist Substances 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XCSBGPAPGUIEFO-OAQYLSRUSA-N n-[(2r)-5-methoxy-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)N3CCOCC3)CC=1C(OC)=CC=C2N1CCN(C)CC1 XCSBGPAPGUIEFO-OAQYLSRUSA-N 0.000 description 2
- IHDRUIHIJWCTIY-JOCHJYFZSA-N n-[(2r)-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=C(C)C2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 IHDRUIHIJWCTIY-JOCHJYFZSA-N 0.000 description 2
- GLCNLSFPYIMZJK-HXUWFJFHSA-N (2r)-5-methoxy-8-(4-methylpiperazin-1-yl)-n-(4-morpholin-4-ylphenyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound C([C@H](CC=12)C(=O)NC=3C=CC(=CC=3)N3CCOCC3)CC=1C(OC)=CC=C2N1CCN(C)CC1 GLCNLSFPYIMZJK-HXUWFJFHSA-N 0.000 description 1
- JMQUFKWBATWTAM-HXUWFJFHSA-N (2r)-5-methoxy-8-(4-methylpiperazin-1-yl)-n-[2-(morpholine-4-carbonyl)phenyl]-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound C([C@H](CC=12)C(=O)NC=3C(=CC=CC=3)C(=O)N3CCOCC3)CC=1C(OC)=CC=C2N1CCN(C)CC1 JMQUFKWBATWTAM-HXUWFJFHSA-N 0.000 description 1
- GLCNLSFPYIMZJK-FQEVSTJZSA-N (2s)-5-methoxy-8-(4-methylpiperazin-1-yl)-n-(4-morpholin-4-ylphenyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound C([C@@H](CC=12)C(=O)NC=3C=CC(=CC=3)N3CCOCC3)CC=1C(OC)=CC=C2N1CCN(C)CC1 GLCNLSFPYIMZJK-FQEVSTJZSA-N 0.000 description 1
- XVMPHVYWWDVFAB-CQSZACIVSA-N (3r)-3-[cyclobutyl(cyclopentyl)amino]-8-fluoro-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound C1CCCC1N([C@H]1COC=2C(F)=CC=C(C=2C1)C(=O)N)C1CCC1 XVMPHVYWWDVFAB-CQSZACIVSA-N 0.000 description 1
- AOSCUPVQGZCMHA-GFCCVEGCSA-N (3r)-3-[cyclobutyl(propan-2-yl)amino]-8-fluoro-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound CC(C)N([C@@H]1CC2=C(C(N)=O)C=CC(F)=C2OC1)C1CCC1 AOSCUPVQGZCMHA-GFCCVEGCSA-N 0.000 description 1
- IAFNMDAKUNVLSN-GFCCVEGCSA-N (3r)-3-[cyclobutyl(propyl)amino]-8-fluoro-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound CCCN([C@@H]1CC2=C(C(N)=O)C=CC(F)=C2OC1)C1CCC1 IAFNMDAKUNVLSN-GFCCVEGCSA-N 0.000 description 1
- HDRGYUKRRPGJKR-LLVKDONJSA-N (3r)-8-fluoro-3-[propan-2-yl(propyl)amino]-3,4-dihydro-2h-chromene-5-carboxamide Chemical compound C1=CC(C(N)=O)=C2C[C@@H](N(C(C)C)CCC)COC2=C1F HDRGYUKRRPGJKR-LLVKDONJSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- OOEQHHKVTDYZTD-OAQYLSRUSA-N 4-morpholin-4-yl-n-[(2r)-8-piperazin-1-yl-1,2,3,4-tetrahydronaphthalen-2-yl]benzamide Chemical compound C([C@H](CC1=2)NC(=O)C=3C=CC(=CC=3)N3CCOCC3)CC1=CC=CC=2N1CCNCC1 OOEQHHKVTDYZTD-OAQYLSRUSA-N 0.000 description 1
- NPFRXRWSLBQFJT-FQEVSTJZSA-N 4-n,4-n-dimethyl-1-n-[(3s)-8-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2h-chromen-3-yl]benzene-1,4-dicarboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C(=O)N[C@H]1CC2=C(N3CCN(C)CC3)C=CC(C)=C2OC1 NPFRXRWSLBQFJT-FQEVSTJZSA-N 0.000 description 1
- GLCNLSFPYIMZJK-UHFFFAOYSA-N 5-methoxy-8-(4-methylpiperazin-1-yl)-n-(4-morpholin-4-ylphenyl)-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound C1=2CC(C(=O)NC=3C=CC(=CC=3)N3CCOCC3)CCC=2C(OC)=CC=C1N1CCN(C)CC1 GLCNLSFPYIMZJK-UHFFFAOYSA-N 0.000 description 1
- GGWPSJWVARDUIR-UHFFFAOYSA-N 8-methoxy-5-(4-methylpiperazin-1-yl)-n-(4-morpholin-4-ylphenyl)-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1=2CC(C(=O)NC=3C=CC(=CC=3)N3CCOCC3)COC=2C(OC)=CC=C1N1CCN(C)CC1 GGWPSJWVARDUIR-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JSPVFUIDFJHLNO-UHFFFAOYSA-N C(CCC)NC1OC2=C(CC1)C=CC=C2F Chemical compound C(CCC)NC1OC2=C(CC1)C=CC=C2F JSPVFUIDFJHLNO-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- BSBVBFLNLYJFBZ-QGZVFWFLSA-N n-[(2r)-5-bromo-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1C1=CC=C(Br)C2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)C(F)(F)F)CC2 BSBVBFLNLYJFBZ-QGZVFWFLSA-N 0.000 description 1
- OXZHFWAHGKDGDI-LJQANCHMSA-N n-[(2r)-5-bromo-8-piperazin-1-yl-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)N3CCOCC3)CC=1C(Br)=CC=C2N1CCNCC1 OXZHFWAHGKDGDI-LJQANCHMSA-N 0.000 description 1
- MQYMBUXUGKGMAK-XMMPIXPASA-N n-[(2r)-5-ethyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-(morpholine-4-carbonyl)benzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)C(=O)N3CCOCC3)CC=1C(CC)=CC=C2N1CCN(C)CC1 MQYMBUXUGKGMAK-XMMPIXPASA-N 0.000 description 1
- BEEWOAIWRLZBGZ-HSZRJFAPSA-N n-[(2r)-5-ethyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)N3CCOCC3)CC=1C(CC)=CC=C2N1CCN(C)CC1 BEEWOAIWRLZBGZ-HSZRJFAPSA-N 0.000 description 1
- WZMSJJIAEOODBC-JOCHJYFZSA-N n-[(2r)-5-methoxy-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-(morpholine-4-carbonyl)benzamide Chemical compound C([C@H](CC=12)NC(=O)C=3C=CC(=CC=3)C(=O)N3CCOCC3)CC=1C(OC)=CC=C2N1CCN(C)CC1 WZMSJJIAEOODBC-JOCHJYFZSA-N 0.000 description 1
- FTCLFWOUOUOQEH-HSZRJFAPSA-N n-[(2r)-8-(4-ethylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(CC)CCN1C1=CC=CC2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 FTCLFWOUOUOQEH-HSZRJFAPSA-N 0.000 description 1
- HWSWMVFTXFBDRW-JOCHJYFZSA-N n-[(2r)-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=CC2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 HWSWMVFTXFBDRW-JOCHJYFZSA-N 0.000 description 1
- VAAMBBBNNWFJHZ-FQEVSTJZSA-N n-[(3s)-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2h-chromen-3-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=CC2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CO2 VAAMBBBNNWFJHZ-FQEVSTJZSA-N 0.000 description 1
- BYJYPZAHTUBRNT-UHFFFAOYSA-N n-[5-bromo-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=C(Br)C2=C1CC(NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 BYJYPZAHTUBRNT-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- MQTUXRKNJYPMCG-CYBMUJFWSA-N robalzotan Chemical compound C1CCC1N([C@H]1COC=2C(F)=CC=C(C=2C1)C(=O)N)C1CCC1 MQTUXRKNJYPMCG-CYBMUJFWSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9703374-0 | 1997-09-18 | ||
| SE9703374A SE9703374D0 (sv) | 1997-09-18 | 1997-09-18 | A new combination |
| PCT/SE1998/001600 WO1999013876A1 (en) | 1997-09-18 | 1998-09-09 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001516717A JP2001516717A (ja) | 2001-10-02 |
| JP2001516717A5 true JP2001516717A5 (https=) | 2006-01-05 |
Family
ID=20408294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000511498A Pending JP2001516717A (ja) | 1997-09-18 | 1998-09-09 | 選択的５−ＨＴ１Ａアンタゴニストおよび選択的ｈ５−ＨＴ１Ｂアンタゴニストまたは部分的アゴニストの組み合わせ |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6159972A (https=) |
| EP (1) | EP1021183B1 (https=) |
| JP (1) | JP2001516717A (https=) |
| KR (1) | KR20010024075A (https=) |
| CN (1) | CN1182847C (https=) |
| AR (1) | AR015447A1 (https=) |
| AT (1) | ATE261728T1 (https=) |
| AU (1) | AU752718B2 (https=) |
| BR (1) | BR9812234A (https=) |
| CA (1) | CA2302383A1 (https=) |
| DE (1) | DE69822490T2 (https=) |
| DK (1) | DK1021183T3 (https=) |
| EE (1) | EE04142B1 (https=) |
| ES (1) | ES2216307T3 (https=) |
| HU (1) | HUP0100401A3 (https=) |
| IL (1) | IL134774A0 (https=) |
| IS (1) | IS5408A (https=) |
| MY (1) | MY116281A (https=) |
| NO (1) | NO20001398L (https=) |
| NZ (1) | NZ503174A (https=) |
| PL (1) | PL339370A1 (https=) |
| PT (1) | PT1021183E (https=) |
| RU (1) | RU2215528C2 (https=) |
| SE (1) | SE9703374D0 (https=) |
| SK (1) | SK2842000A3 (https=) |
| TR (1) | TR200000734T2 (https=) |
| TW (1) | TW568786B (https=) |
| WO (1) | WO1999013876A1 (https=) |
| ZA (1) | ZA987810B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9601110D0 (sv) | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| WO2002066454A1 (fr) * | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Derives de chromene |
| ATE424825T1 (de) * | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
| USD969016S1 (en) | 2021-06-28 | 2022-11-08 | Koninklijke Asscher Diamant Maatschappij B.V. | Rose oval diamond article |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA90673B (en) * | 1989-02-02 | 1990-10-31 | Yamanouchi Pharma Co Ltd | Tetrahydrobenzimidazole derivatives |
| PT533268E (pt) * | 1991-09-18 | 2002-02-28 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d |
| GB9410512D0 (en) * | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| FI961247A0 (fi) * | 1996-03-18 | 1996-03-18 | Finnish Peroxides Ab Oy | Foerfarande foer loesning av uppsvaellningsproblem i en avfalls vattenreningsanordning foer kontroll av traodartiga bakterier |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
-
1997
- 1997-09-18 SE SE9703374A patent/SE9703374D0/xx unknown
-
1998
- 1998-08-27 ZA ZA987810A patent/ZA987810B/xx unknown
- 1998-08-29 TW TW087114345A patent/TW568786B/zh not_active IP Right Cessation
- 1998-09-09 US US09/171,581 patent/US6159972A/en not_active Expired - Fee Related
- 1998-09-09 CN CNB988112493A patent/CN1182847C/zh not_active Expired - Fee Related
- 1998-09-09 ES ES98944374T patent/ES2216307T3/es not_active Expired - Lifetime
- 1998-09-09 AT AT98944374T patent/ATE261728T1/de not_active IP Right Cessation
- 1998-09-09 PT PT98944374T patent/PT1021183E/pt unknown
- 1998-09-09 RU RU2000109558/14A patent/RU2215528C2/ru not_active IP Right Cessation
- 1998-09-09 NZ NZ503174A patent/NZ503174A/en unknown
- 1998-09-09 BR BR9812234-7A patent/BR9812234A/pt not_active IP Right Cessation
- 1998-09-09 EE EEP200000143A patent/EE04142B1/xx not_active IP Right Cessation
- 1998-09-09 HU HU0100401A patent/HUP0100401A3/hu unknown
- 1998-09-09 CA CA002302383A patent/CA2302383A1/en not_active Abandoned
- 1998-09-09 KR KR1020007002821A patent/KR20010024075A/ko not_active Ceased
- 1998-09-09 SK SK284-2000A patent/SK2842000A3/sk unknown
- 1998-09-09 JP JP2000511498A patent/JP2001516717A/ja active Pending
- 1998-09-09 DE DE69822490T patent/DE69822490T2/de not_active Expired - Fee Related
- 1998-09-09 PL PL98339370A patent/PL339370A1/xx unknown
- 1998-09-09 EP EP98944374A patent/EP1021183B1/en not_active Expired - Lifetime
- 1998-09-09 AU AU91929/98A patent/AU752718B2/en not_active Ceased
- 1998-09-09 TR TR2000/00734T patent/TR200000734T2/xx unknown
- 1998-09-09 WO PCT/SE1998/001600 patent/WO1999013876A1/en not_active Ceased
- 1998-09-09 IL IL13477498A patent/IL134774A0/xx unknown
- 1998-09-09 DK DK98944374T patent/DK1021183T3/da active
- 1998-09-16 MY MYPI98004226A patent/MY116281A/en unknown
- 1998-09-17 AR ARP980104633A patent/AR015447A1/es unknown
-
2000
- 2000-03-15 IS IS5408A patent/IS5408A/is unknown
- 2000-03-17 NO NO20001398A patent/NO20001398L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001516718A5 (https=) | ||
| JP2001516719A5 (https=) | ||
| RU2214824C2 (ru) | Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b | |
| RU2000109563A (ru) | Комбинация обратного поглощения 5-нт селективного антагониста или частичного агониста н5-нт1b | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| JP2003528917A5 (https=) | ||
| JP2020023528A5 (https=) | ||
| JP2005501120A5 (https=) | ||
| EP3219308A1 (en) | Melt-extruded solid dispersions containing an apoptosis-inducing agent | |
| JP2004504404A5 (https=) | ||
| RU2004131641A (ru) | Новые соединения | |
| ITRM920155A1 (it) | Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi | |
| JP2004513881A5 (https=) | ||
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| JP2005524628A5 (https=) | ||
| JP2005506352A5 (https=) | ||
| JP2007525518A5 (https=) | ||
| JP2008538741A (ja) | 鬱病の治療用及び／又は予防用の医薬組成物 | |
| RU2005102098A (ru) | Амидное производное | |
| JP2018512403A5 (https=) | ||
| JP2001516717A5 (https=) | ||
| RU2003130635A (ru) | Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболевания, подобных аллергическим нарушениям | |
| RU2350618C2 (ru) | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ | |
| JP2020519659A5 (https=) | ||
| RU2215528C2 (ru) | Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b |